eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
2/2008
vol. 46
 
Share:
Share:
more
 
 
abstract:

Original paper
Leflunomide for the treatment of rheumatoid arthritis after methotrexate failure. Efficacy and prognostic factors for response

Aleksandra Zoń-Giebel
,
Małgorzata Dec
,
Danuta Kapołka

Reumatologia 2008; 46, 2: 55–61
Online publish date: 2008/04/25
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The goal of this study, including 87 rheumatoid arthritis (RA) patients, was to evaluate the long-term efficacy of leflunomide administered after methotrexate failure, as well as to determine prognostic factors for the probability of good therapeutic response. Evaluation of the response durability was the secondary aim. The probability of good therapeutic response (DAS28 reduction >1.2), analyzed as cumulative incidence, equalled 57% at 30 months. Good response occurred in the early months of therapy as well as after 24 months. In a univariate and multivariate analysis initial WBC>10 × 109/l was associated with increased response rate, while radiological stage 4 resulted in decreased chance of a good response. For patients who achieved the response, the two-year probability of therapy continuation without RA progression was 87%. We conclude that leflunomide is effective in RA patients after methotrexate failure. The therapy should be long-lasting as the response may occur late. Our results allow better selection of candidates for leflunomide treatment.
keywords:

leflunomide, rheumatoid arthritis, prognostic factors



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe